News | News By Subject | News by Disease News By Date | Search News

Overactive Bladder News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
FDA OKs Merck & Co., Inc. (MRK) OTC Version of Overactive Bladder Drug     1/28/2013
Pfizer Inc. (PFE) Reports Positive Results in Studies of Toviaz, Pristiq, Chantix     1/24/2013
Allergan Inc. (AGN)'s Botox Gets FDA Approval for Overactive Bladder     1/23/2013
Merck & Co., Inc. (MRK) May Not Have Shown Women Can Safely Choose Drug     11/8/2012
Allergan Inc. (AGN)'s Botox Shot Helps Overactive Bladder in Women     10/4/2012
FDA Approves Astellas Pharma Inc. (YPH.BE) Drug for Leaky Bladder     7/2/2012
Astellas Pharma Inc. (ALPMY) Wins FDA Panel Backing for Overactive Bladder Drug     4/6/2012
Astellas Pharma Inc. (YPH.BE) Overactive Bladder Drug Raises Blood Pressure Dangers, FDA Says     4/3/2012
Allergan Inc. (AGN) Says Botox Reduces Urinary Incontinence Symptoms in Two Studies     3/28/2012
FDA OKs Antares Pharma, Inc. (AIS) Overactive Bladder Gel     12/8/2011
Pfizer Inc. (PFE)'s Kidney Cancer Drug May Not Be Effective, FDA Says     12/7/2011
Astellas Pharma US Announces Positive Phase III Results Showing Mirabegron Improves Key OAB Symptoms     5/18/2011
Warner Chilcott, PLC (WCRX) Agrees to Terminate Existing Co-Promotion Agreement With Novartis AG and Acquire U.S. Rights to Enablex(R) Overactive Bladder Treatment for $400 Million in Cash     9/24/2010

News from Around the Web
Electricity May Spark Medical Treatment     9/30/2015
Common Myth That Urine Is Sterile Debunked, Loyola University Chicago Stritch School Of Medicine Study     5/20/2014
Fesoterodine Shows Rare Efficacy in Treating Nocturia in Patients With Overactive Bladder: Presented at AUGS, University of South Carolina Study     10/6/2010
For People With Overactive Bladders Botox Injections Can Significantly Improve Quality Of Life, Guy's Hospital and King's College London Study     6/11/2009
Botox® May Help Spinal Cord-Injured or Multiple Sclerosis Patients with Overactive Bladder, Baylor College of Medicine Study     9/21/2007
Scientists Make Breakthrough In Understanding Muscle Contraction     7/29/2005
The Bladder Does Not Shrink With Age     5/26/2005
Novartis' (NVS) Enablex Gets FDA Thumbs-Up     12/23/2004

Press Releases
American Urological Association Release: Overactive Bladder Treatment Linked To Decreased Fall Risk For Older Adults     5/18/2015
Allergan Inc. (AGN) Release: Nearly Half Of Women In New Survey Reveal That Their Current Treatments Are Not Adequately Addressing Overactive Bladder (OAB) Symptoms     8/19/2014
Lipella Pharmaceuticals Release: Positive Clinical Trial Results Of Topical Botulinum Toxin For Overactive Bladder     4/8/2014
AltheRx is Granted U.S. Patent for Use of Solabegron in Combination With Antimuscarinics for the Treatment of Overactive Bladder     10/17/2013
Astellas Pharma Inc. (YPH.BE) Helps Patients Identify with their "OAB Reality"     7/24/2013
Targacept, Inc. (TRGT) Announces Initiation of Phase 2b Study of TC-5214 in Overactive Bladder     5/29/2013
SALVAT and Kwang Dong Pharmaceutical Announced Positive Results of Phase IIb for Tarafenacin for Overactive Bladder Treatment     4/10/2013
Mylan Pharmaceuticals, Inc. (MYL) Gets FDA Approval for New Product     11/29/2012
Targacept, Inc. (TRGT) Announces Plans to Develop TC-5214 in Overactive Bladder     9/5/2012
AltheRx Presents Positive Phase II Results of Solabegron in Overactive Bladder at the European Association of Urology Congress     3/1/2012
Pfizer Inc. (PFE)’s Toviaz Shows Positive Top-Line Primary Endpoint Result In Study Of Overactive Bladder In Vulnerable Elderly Patients     12/6/2011
Provesica Publishes XEN-D0501 Phase 1 Data on Innovative new Medicine for Overactive Bladder     11/23/2011
Pfizer Inc. (PFE) Release: Toviaz Top-Line Primary Endpoint Results Positive In Overactive Bladder Study of Nocturnal Urinary Urgency     11/8/2011
TheraVida Initiates Phase 2 Trial of THVD-201 for Overactive Bladder and Urinary Incontinence     5/16/2011
Antares Pharma, Inc. (AIS) Announces FDA Acceptance of Anturol(R) NDA for Filing     4/8/2011

//-->